Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)
Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –
Lakefront Biotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was -€257.46M. The highest annual figure on record is €3.21B in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€257.46M | – |
| FY2024 | Dec 31, 2024 | -€320.03M | – |
| FY2023 | Dec 31, 2023 | -€405.97M | – |
| FY2022 | Dec 31, 2022 | -€500.54M | – |
| FY2021 | Dec 31, 2021 | -€503.83M | – |
| FY2020 | Dec 31, 2020 | -€427.34M | -113.3% |
| FY2019 | Dec 31, 2019 | €3.21B | – |
| FY2018 | Dec 31, 2018 | -€142.47M | – |
| FY2017 | Dec 31, 2017 | -€147.03M | -161.4% |
| FY2016 | Dec 31, 2016 | €239.40M | – |
| FY2015 | Dec 31, 2015 | -€114.59M | – |
See a number that looks wrong?